Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Body weight reductions of a mean of 11.6% after 28 weeks with ...

Clinical trials show weight loss between 15% to 21% for GLP-1s, but this study suggests that weight loss in the real world is ...

Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.

Around 1.5 million Brits are now taking weight-loss drugs, such as Mounjaro, and pharmacists are warning users to be careful in the heatwave ...

Experts and organizations call for stricter regulations on how such medications are prescribed – Side effect reports under ...

'Ozempic Penis' is the new side-effect that people have been turning their heads at, and users are reporting experiencing ...

She lost 250 pounds and thought her journey was over... but then she discovered something most people don't talk about.

A new study is showing the effectiveness of GLP-1 medication, commonly referred to as weight loss drugs, and how they stack ...

Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

Although GLP-1 drugs make headlines for vision risks, other weight-loss medications carry their own eye-related side effects.

The side effects of taking Mounjaro can be very varied, and the drug tends to affect people differently. The most common side effects include feeling sick, diarrhoea, constipation, vomiting, heartburn ...

This study adds to the growing evidence that while GLP-1 medications can be helpful for some patients, bariatric surgery remains the most powerful option for substantial and lasting weight ...